# US 2022/0089740 A1 · Tim-3 antibodies and combinations with other checkpoint inhibitors for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0089740 A1
- Document ID: US20220089740A1
- Status: Published application
- Kind: A1
- Application number: 17/420,189
- Filed: 2020-01-03
- Published: 2022-03-24
- Earliest claimed: 2019-01-11
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Mythili KONERU; Maria de las Nieves VELEZ DE MENDIZABAL CASTILLO
- Web page: https://patentgrep.com/patent/US20220089740A1

## CPC

- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/30: from tumour cells
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to dosing regimens for antibodies that bind human T-cell immunoglobulin- and mucin-domain-containing protein-3 (TIM-3), and may be useful for treating tumors in combination with anti-human PD-L1 antibodies, anti-human PD-1 antibodies, chemotherapy, and ionizing radiation as well as the use of said antibodies for the treatment of solid tumors that are mismatch repair deficient or exhibit a high degree of microsatellite instability.

## Claims

### Claim 1

A method of treating cancer comprising administering an anti-human TIM-3 antibody to a human patient in need thereof with a dose in the range of 1 mg to 1800 mg, wherein the anti-human TIM-3 antibody comprises a light chain having the amino acid sequence of SEQ ID NO: 10 and a heavy chain having the amino acid sequence of SEQ ID NO: 11.

### Claim 2 (depends on 1)

The method of claim 1, wherein the dose is administered once every two weeks.

### Claim 3 (depends on 2)

The method of claim 2, wherein the dose is in the range of 30 mg to 1200 mg.

### Claim 4 (depends on 2)

The method of claim 2, wherein the dose is 30 mg.

### Claim 5 (depends on 2)

The method of claim 2, wherein the dose is 70 mg.

### Claim 6 (depends on 2)

The method of claim 2, wherein the dose is 200 mg.

### Claim 7 (depends on 2)

The method of claim 2, wherein the dose is 600 mg.

### Claim 8 (depends on 1)

The method of claim 1, wherein the dose is administered once every three weeks.

### Claim at position 9

-13. (canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the anti-TIM-3 antibody is administered with a loading dose followed by a maintenance dose, wherein the loading dose is administered once every two to three weeks for one to three cycles, the maintenance dose is administered once every two to three weeks following completion of the loading dose, the loading dose and the maintenance doses are in the range of 1 mg to 1800 mg, and the maintenance dose is a lower dosage amount than the loading dose.

### Claim 15

(canceled)

### Claim 16 (depends on 14)

The method of claim 14, wherein the loading dose is 1200 mg administered once every two weeks for two cycles, and the maintenance dose is 600 mg administered once every two weeks.

### Claim 17 (depends on 14)

The method of claim 14, wherein the loading dose is 1800 mg administered once every three weeks for three cycles, and the maintenance dose is 900 mg administered once every three weeks.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The method of claim 1, wherein the anti-human TIM-3 antibody is administered in combination with an effective amount of an anti-human PD-L1 (SEQ ID NO: 14) antibody or an effective amount of an anti-human PD-1 (SEQ ID NO: 15) antibody.

### Claim 20 (depends on 19)

The method of claim 19, wherein the anti-human PD-L1 antibody is durvalumab, atezolizumab, or avelumab.

### Claim 21 (depends on 19)

The method of claim 19, wherein the anti-human PD-L1 antibody comprises a light chain having the amino acid sequence of SEQ ID NO: 12 and a heavy chain having the amino acid sequence of SEQ ID NO: 13.

### Claim 22 (depends on 19)

The method of claim 19, wherein the anti-human PD-L1 antibody is administered at a dose of about 35 mg to about 1800 mg.

### Claim 23 (depends on 22)

The method of claim 22, wherein the dose of the anti-human PD-L1 antibody is administered once every two weeks.

### Claim at position 20

-35. (canceled)

### Claim 36 (depends on 19)

The method of claim 19, wherein the anti-human PD-1 antibody is administered and is pembrolizumab, nivolumab, or cemiplimab.

### Claim at position 22

-39. (canceled)

### Claim 40 (depends on 1)

The method of claim 1, wherein the patient was previously treated with an anti-human PD-L1 antibody or an anti-human PD-1 antibody.

### Claim 41 (depends on 1)

The method of claim 1, wherein the patient has not been previously treated with an anti-human PD-L1 antibody or an anti-human PD-1 antibody.

### Claim 42 (depends on 1)

The method of claim 1, wherein the cancer is a solid tumor.

### Claim 43 (depends on 42)

The method of claim 42, wherein the solid tumor is PD-L1 high.

### Claim 44 (depends on 42)

The method of claim 42, wherein the solid tumor is PD-L1 low.

### Claim 45 (depends on 42)

The method of claim 42, wherein the solid tumor has a high degree of microsatellite instability.

### Claim 46 (depends on 42)

The method of claim 42, wherein the solid tumor is mismatch repair deficient.

### Claim 47 (depends on 42)

The method of claim 42, wherein the solid tumor has a high degree of microsatellite instability and is mismatch repair deficient.

### Claim 48 (depends on 1)

The method of claim 1, wherein the cancer is melanoma, lung cancer, head and neck cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, esophageal cancer, soft tissue sarcoma, liver cancer, gallbladder cancer, cervical cancer, duodenal cancer, bone cancer, neuroendocrine cancer, intestinal cancer.

### Claim 49 (depends on 48)

The method of claim 48, wherein the cancer is melanoma or non-small cell lung cancer.

### Claim 50 (depends on 1)

The method of claim 1, wherein the anti-human TIM-3 antibody is administered with ionizing radiation.

### Claim at position 34

-150. (canceled)
